Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management.
Couture F, Turner AR, Melosky B, et al.
Oncologist 2005;10(1):63-71.
Review by
A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
Schwartzberg LS, Yee LK, Senecal FM, et al.
Oncologist 2004;9(6):696-707.
Review by
Can erythropoietin therapy improve survival?
Glaspy J, Dunst J
Oncology 2004;67 Suppl 1:5-11.
Review by
Tandem high-dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion.
Baron F, Frere P, Fillet G, Beguin Y
Br J Haematol 2003;123(1):103-105.
Review by
Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial.
Henke M, Laszig R, Rube C, et al.
Lancet 2003;362:1255-1260.
Review by
Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: Results of a randomized, controlled trial.
Iconomou G, Koutras A, Rigopoulos A, Vagenakis AG, Kalofonos HP
J Pain Symptom Manage 2003;25(6):512-518.
Review by
Multivariate predictors of blood product use in cardiac surgery.
Parr KG, Patel MA, Dekker R, et al.
J Cardiothorac Vasc Anesth 2003;17(2):176-181.
Review by
Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy – results of a randomized trial.
Glossmann JP, Engert A, Wassmer G, et al.
Ann Hematol 2003;82(8):469-475.
Review by Henry DH
Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study.
Hedenus M, Adriansson M, Miguel JS, et al.
Br J Haematol 2003;122(3):394-403.
Review by
Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production.
Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B
Br J Haematol 2003;122(3):386-393.
Review by
Hemoglobin concentrations influence birth outcomes in pregnant african-american adolescents.
Chang SC, O'Brien KO, Nathanson MS, Mancini J, Witter FR
J Nutr 2003;133(7):2348-2355.
Impact of tumor hypoxia and anemia on radiation therapy outcomes.
Harrison LB, Chadha M, Hill RJ, Hu K, Shasha D
Oncologist 2002;7(6):492-508.
Review by
The effects of epoetin alfa on transfusion requirements in head and neck cancer patients: a prospective, randomized, placebo-controlled study.
Scott SN, Boeve TJ, McCulloch TM, Fitzpatrick KA, Karnell LH
Laryngoscope 2002;112(7):1221-1229.
Review by Henry DH
Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy.
This is a well done study of anemic cancer patients on cisplatin chemotherapy that documents nicely that the best predictor of an ultimate good response... Read More
How effective is acute normovolaemic haemodilution in femoro-distal bypass surgery?
Spark JI, Chetter IC, Kester RC, Scott DJA
Cardiovasc Surg 2002;10(5):460-463.
Review by Van der Linden P
NATA: Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis
MISSION: Providing a multidisciplinary forum for dialogue between haematologists, transfusion medicine specialists, anaesthesiologists, intensive care and emergency physicians, surgeons, perfusionists, nurses, biomedical scientists and other healthcare professionals.
Sitemap
Contact us
- secretary@nataonline.com
-
NATA
Rue de l’Industrie 24
1040 Bruxelles - VAT: 0781668659